Mri Tumor Monitoring
Mri Tumor Monitoring - Related Videos
04:11
DCE-MRI of Orthotopic Pancreatic Tumor Xenografts: A Method to Assess Microvasculature in a Target Tumor Tissue
0 Views •
2023
This video describes the technique of DCE-MRI for orthotropic pancreatic tumor xenografts in mice. DCE-MRI is a non-invasive method to analyze microvasculature in a target tissue, and useful to assess vascular response in a tumor following a novel therapy. This method will assist investigators to apply DCE-MRI for orthotopic gastrointestinal cancer mouse models.
07:35
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
0 Views •
Cited by 14 •
2015
The use of ultra-high field MRI as a non-invasive way to obtain phenotypic information of rodent models for polycystic kidney disease and to monitor interventions is described. Compared with the traditional histological approach, MRI images can be acquired in vivo, allowing for longitudinal follow-up.
04:37
Sampling Prostate Cancer Tissue for Biobanking: An MRI-guided Targeted Technique to Remove Biopsy Punches from Fresh Tumor Tissue
0 Views •
2023
This video demonstrates an MRI data-based technique to target specific tumor-containing regions in prostate tissue for sampling. The collected biopsy specimens can be either stored for biobanking purposes or used for subsequent downstream analysis.
06:26
PTM Based Tumor Microenvironment Monitoring: A Method for Tracking Changes in ECM Rigidity Using Tumor Spheroids
0 Views •
2023
This protocol describes a technique for monitoring extracellular matrix rigidity changes by using particle-tracking microrheology (PTM). This is done by culturing 3D pancreatic tumor spheroids into ECM with embedded fluorescent probes for video particle-tracking and analysis.
12:27
Noninvasive In Vivo Small Animal MRI and MRS: Basic Experimental Procedures
0 Views •
Cited by 9 •
2009
This work describes basic procedures of noninvasive small animal MRI and MRS in vivo.
FAQs
Its value extends beyond measuring tumor size. Comparing scans can reveal changes in internal structure, tissue characteristics, and contrast-agent uptake. These dimensions can show that a tumor has changed even when size alone does not capture the observed difference. In cancer research, these measurements help characterize progression or treatment response more comprehensively.
Repeated scans create a longitudinal record of disease status. By examining tumor growth, progression, or treatment-related effects over time, researchers can evaluate how disease behaves and whether an intervention is associated with imaging changes. This time-based perspective supports studies that require serial observation rather than relying on a single snapshot.
Contrast-agent uptake is one of the tissue-related features that can be tracked across MRI examinations. Researchers compare how uptake appears in successive images alongside tumor size, structure, and other tissue characteristics. This adds another dimension to treatment-response assessment and may help distinguish changes in tumor status that are not fully represented by measurements of size alone.
The absence of ionizing radiation makes MRI suitable for repeated observations when a study requires serial assessments. This supports longitudinal cancer research and ongoing evaluation of tumor growth, progression, or therapeutic effects without adding ionizing radiation from the imaging method itself. Repeatability is especially relevant when investigators need to compare disease status at multiple time points.
At each monitoring time point, MRI produces images that can be assessed for tumor size, structure, tissue characteristics, and contrast-agent uptake. Investigators then compare those features across scans to identify changes. This repeated-measurement workflow turns individual images into a longitudinal record that can support conclusions about growth, progression, or response to therapy.
Researchers use the approach in longitudinal cancer studies to examine tumor growth and progression and to evaluate therapeutic effects. Because the same general imaging strategy can provide repeated, noninvasive observations, it helps investigators follow disease status over time rather than relying only on isolated assessments. The resulting comparisons can contribute to treatment evaluation and research interpretation.
Measurements from serial MRI scans can inform treatment planning by showing how tumor size, structure, tissue characteristics, or contrast-agent uptake change over time. They also support evaluation of imaging biomarkers in cancer research, where these image-derived measurements can be related to tumor status or therapeutic effects. These uses connect repeated imaging with personalized oncology.